Borenius advised Nanoform Finland Plc on its Nasdaq First North Premier Finland & Sweden IPO

We advised Nanoform Finland Plc on its EUR 88 million initial public offering (“IPO”) to Nasdaq First North Premier Finland & Sweden. Nanoform launched the First North Premier segment in Finland and the trading in the company’s shares began on 4 June 2020 both in Finland and in Sweden. Advokatfirman Vinge KB acted as our co-counsel for Nanoform on matters concerning Swedish law.

Nanoform’s IPO is also the largest listing on the First North market place in Finland with an offering size of EUR 88 million corresponding to a market capitalisation of EUR 230 million immediately before the commencement of trading.

Nanoform, founded in 2015 as a spin-out from the University of Helsinki, is an expert in nanotechnology and drug particle engineering. The Company’s mission is to enable a significant increase in the number of drugs that progress to clinical trials and reach the market. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology.

Borenius has acted as Nanoform’s advisor from the moment the company was established. We have been there to advise the company through each phase of the development of its business. Borenius breadth of expertise across practice areas, market leading life sciences capabilities, and broad international network is ideally placed to support fast moving and ambitious companies. We believe that this successful IPO is another testament to the added value that is created when we act as a close partner to our clients beyond the traditional role of legal counsel. This is particularly true for companies like Nanoform developing novel technologies in a highly regulated industry.